Dr. Abgaryan has more than 15 years of experience in the field of drug discovery and small molecule pharmacology. Dr. Abgaryan had a track record of 3 IND submissions, a number of PubChem molecular structure discoveries and one FDA - approved drug, Ozanimod, for treatment of Multiple Sclerosis and Ulcerative Colitis. Throughout her career, she developed multiple assays for high throughput drug screening and a number of genetically modified cell lines as essential tools in drug discovery.
Dr. Abgaryan She is the invitro-pharmacologist for the lead discovery of drugs targeting KOR Antagonist and V1aR Antagonist receptors that are currently in clinical phases 2 and 1 in the pipeline. She directly contributed to 7 start-ups and incubators from early-stage set-up, business development and market entry. i. Dr. Lucy Abgaryan has an undergraduate degree in physics and PhD in Biophysics from Yerevan State University, and an MBA from the University of California San Diego (UCSD).
Dr. Abgaryan continues her education at The Scripps Research Institute as a postdoctoral fellow developing small molecule drugs for a number of disorders.